Microenvironmental influences in chronic lymphocytic leukaemia: The role of antigen stimulation

Journal of Internal Medicine

Volumn 264, Issue 6, 2008, Pages 549-562

  Ghia, P ^a   Chiorazzi, N ^b,c,d   Stamatopoulos, K ^e  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

(auto)antigen; Anergy; Apoptosis; B cell receptor; CLL; Microenvironment

Indexed keywords

AUTOANTIGEN; B LYMPHOCYTE RECEPTOR; BREAKPOINT CLUSTER REGION PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE; CHEMOKINE RECEPTOR; HAPTEN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 4; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

APOPTOSIS; B LYMPHOCYTE; CELL CONTACT; CELL INTERACTION; CELL KINETICS; CELL PROLIFERATION; CELL STIMULATION; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CLONAL ANERGY; CONFERENCE PAPER; GENE; GENE EXPRESSION; GENE MUTATION; GENE STRUCTURE; GENETIC ASSOCIATION; HCDR3 GENE; HUMAN; IGHD GENE; IGHD3 16 GENE; IGHJ GENE; IGHJ3 GENE; IGHV GENE; IGHV1 69 GENE; IGHV3 21 GENE; IGHV4 34 GENE; IGKV GENE; IGKV2 30 GENE; IGKV3 20 GENE; IGLV GENE; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; LEUKEMIA CELL; LYMPHOCYTE CULTURE; MICROENVIRONMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; STEREOTYPY; STROMA CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, CD40; AUTOANTIGENS; B-LYMPHOCYTES; CD40 LIGAND; CHEMOKINES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 55949116983     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02030.x     Document Type: Conference Paper

References (97)

1. Ghia P, Ferreri AM, Galigaris-Cappio F. Chronic lymphocytic leukemia. Crit Rev Oncol Hematol 2007 64 : 234 46.
2. Ghia P, Caligaris-Cappio F. The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 2000 79 : 157 73.
3. Dohner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1910 6.
4. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002 99 : 15524 9.
5. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005 102 : 13944 9.
6. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006 107 : 1761 7.
7. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003 123 : 380 8.
8. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998 91 : 2387 96.
9. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996 92 : 97 103.
10. Ghia P, Circosta P, Scielzo C et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol 2005 294 : 135 45.
11. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993 177 : 925 35.
12. Granziero L, Circosta P, Scielzo C et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood 2003 101 : 1962 9.
13. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000 96 : 2655 63.
14. Buske C, Gogowski G, Schreiber K, Rave-Frank M, Hiddemann W, Wormann B. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp Hematol 1997 25 : 329 37.
15. Granziero L, Ghia P, Circosta P et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001 97 : 2777 83.
16. Patten PE, Buggins AG, Richards J et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008 111 : 5173 81.
17. Ghia P, Strola G, Granziero L et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002 32 : 1403 13.
18. Yellin MJ, Sinning J, Covey LR et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994 153 : 666 74.
19. Pizzolo G, Chilosi M, Ambrosetti A, Semenzato G, Fiore-Donati L, Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood 1983 62 : 1289 96.
20. Takemura S, Braun A, Crowson C et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001 167 : 1072 80.
21. Corcione A, Aloisi F, Serafini B et al. B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmun Rev 2005 4 : 549 54.
22. Pileri SA, Ascani S, Sabattini E et al. The pathologist's view point. Part I - indolent lymphomas. Haematologica 2000 85 : 1291 307.
23. Damle RN, Batliwalla FM, Ghiotto F et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood 2004 103 : 375 82.
24. Terrin L, Trentin L, Degan M et al. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 2007 21 : 965 72.
25. Messmer BT, Messmer D, Allen SL et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005 115 : 755 64.
26. Nishio M, Endo T, Tsukada N et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005 106 : 1012 20.
27. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999 94 : 3658 67.
28. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996 184 : 1101 9.
29. Chu P, Deforce D, Pedersen IM et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002 99 : 3854 9.
30. Damle RN, Ghiotto F, Valetto A et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002 99 : 4087 93.
31. Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001 194 : 1625 38.
32. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008 22 : 211 9.
33. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999 94 : 1840 7.
34. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003 101 : 4944 51.
35. Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003 101 : 1087 93.
36. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007 109 : 4424 31.
37. Muzio M, Apollonio B, Scielzo C et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008 112 : 188 95.
38. Merrell KT, Benschop RJ, Gauld SB et al. Identification of anergic B cells within a wild-type repertoire. Immunity 2006 25 : 953 62.
39. Fais F, Ghiotto F, Hashimoto S et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998 102 : 1515 25.
40. Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood 2003 101 : 3082 4.
41. Widhopf GF 2nd., Kipps TJ. Normal B cells express 51p1-encoded Ig heavy chains that are distinct from those expressed by chronic lymphocytic leukemia B cells. J Immunol 2001 166 : 95 102.
42. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999 94 : 1848 54.
43. Tobin G, Thunberg U, Johnson A et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002 99 : 2262 4.
44. Tobin G, Thunberg U, Johnson A et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003 101 : 4952 7.
45. Widhopf GF 2nd., Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004 104 : 2499 504.
46. Messmer BT, Albesiano E, Efremov DG et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004 200 : 519 25.
47. Tobin G, Thunberg U, Karlsson K et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004 104 : 2879 85.
48. Stamatopoulos K, Belessi C, Moreno C et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007 109 : 259 70.
49. Murray F, Darzentas N, Hadzidimitriou A et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008 111 : 1524 33.
50. Vargas-Madrazo E, Lara-Ochoa F, Ramirez-Benites MC, Almagro JC. Evolution of the structural repertoire of the human V(H) and Vkappa germline genes. Int Immunol 1997 9 : 1801 15.
51. Ghiotto F, Fais F, Valetto A et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004 113 : 1008 16.
52. Ghia P, Stamatopoulos K, Belessi C et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005 105 : 1678 85.
53. Silberstein LE, Jefferies LC, Goldman J et al. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood 1991 78 : 2372 86.
54. Potter KN, Hobby P, Klijn S, Stevenson FK, Sutton BJ. Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen. J Immunol 2002 169 : 3777 82.
55. Silberstein LE, George A, Durdik JM, Kipps TJ. The V4-34 encoded anti-i autoantibodies recognize a large subset of human and mouse B-cells. Blood Cells Mol Dis 1996 22 : 126 38.
56. Pugh-Bernard AE, Silverman GJ, Cappione AJ et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001 108 : 1061 70.
57. Jang YJ, Stollar BD. Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol Life Sci 2003 60 : 309 20.
58. Li H, Jiang Y, Prak EL, Radic M, Weigert M. Editors and editing of anti-DNA receptors. Immunity 2001 15 : 947 57.
59. Radic MZ, Mackle J, Erikson J, Mol C, Anderson WF, Weigert M. Residues that mediate DNA binding of autoimmune antibodies. J Immunol 1993 150 : 4966 77.
60. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. Blood 2004 103 : 3490 5.
61. Silverman GJ, Goldfien RD, Chen P et al. Idiotypic and subgroup analysis of human monoclonal rheumatoid factors. Implications for structural and genetic basis of autoantibodies in humans. J Clin Invest 1988 82 : 469 75.
62. Adderson EE, Shackelford PG, Quinn A et al. Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J Clin Invest 1993 91 : 2734 43.
63. Casadevall A, Scharff MD. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med 1991 174 : 151 60.
64. Insel RA, Adderson EE, Carroll WL. The repertoire of human antibody to the Haemophilus influenzae type b capsular polysaccharide. Int Rev Immunol 1992 9 : 25 43.
65. Sanz I, Capra JD. V kappa and J kappa gene segments of A/J Ars-A antibodies: somatic recombination generates the essential arginine at the junction of the variable and joining regions. Proc Natl Acad Sci U S A 1987 84 : 1085 9.
66. Wysocki LJ, Gridley T, Huang S, Grandea AG 3rd., Gefter ML. Single germline VH and V kappa genes encode predominating antibody variable regions elicited in strain A mice by immunization with p-azophenylarsonate. J Exp Med 1987 166 : 1 11.
67. Hayakawa K, Hardy RR, Parks DR, Herzenberg LA. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J Exp Med 1983 157 : 202 18.
68. Chen X, Martin F, Forbush KA, Perlmutter RM, Kearney JF. Evidence for selection of a population of multi-reactive B cells into the splenic marginal zone. Int Immunol 1997 9 : 27 41.
69. Borche L, Lim A, Binet JL, Dighiero G. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990 76 : 562 9.
70. Broker BM, Klajman A, Youinou P et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988 1 : 469 81.
71. Sthoeger ZM, Wakai M, Tse DB et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989 169 : 255 68.
72. Riboldi P, Kasaian M, Mantovani L, Ikematsu H, Casali P. Natural Antibodies. New York : Harwood Academic Publishers, 1992.
73. Herve M, Xu K, Ng YS et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005 115 : 1636 43.
74. Lanemo Myhrinder A, Hellqvist E, Sidorova E et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008 111 : 3838 48.
75. Chu C, Catera R, Hatzi K et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize non-muscle myosin heavy chain IIA. Blood 2008 Sep 23. [Epub ahead of print].
76. Kato M, Fukuda H, Nonaka T, Imajoh-Ohmi S. Cleavage of nonmuscle myosin heavy chain-A during apoptosis in human Jurkat T cells. J Biochem 2005 137 : 157 66.
77. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol 2006 79 : 489 98.
78. Zhang M, Alicot EM, Chiu I et al. Identification of the target self-antigens in reperfusion injury. J Exp Med 2006 203 : 141 52.
79. Catera R, Hatzi K, Chu C et al. Polyreactive monoclonal antibodies synthesized by some B-CLL cells recognize specific antigens on viable and apoptotic T cells. Blood 2006 108 : 796a.
80. Catera R, Silverman GJ, Hatzi K et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008 in press.
81. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994 179 : 1317 30.
82. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004 172 : 6692 700.
83. Chang MK, Bergmark C, Laurila A et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A 1999 96 : 6353 8.
84. Chou MY, Hartvigsen K, Hansen LF et al. Oxidation-specific epitopes are important targets of innate immunity. J Intern Med 2008 263 : 479 88.
85. Chang MK, Binder CJ, Miller YI et al. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med 2004 200 : 1359 70.
86. Yla-Herttuala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989 84 : 1086 95.
87. Shaw PX, Goodyear CS, Chang MK, Witztum JL, Silverman GJ. The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis- associated neo-antigens and apoptotic cells. J Immunol 2003 170 : 6151 7.
88. Gearhart PJ, Johnson ND, Douglas R, Hood L. IgG antibodies to phosphorylcholine exhibit more diversity than their IgM counterparts. Nature 1981 291 : 29 34.
89. Shaw PX, Horkko S, Chang MK et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000 105 : 1731 40.
90. Hatzi K, Catera R, Ferrarini M et al. B-cell chronic lymphocytic leukemia (B-CLL) cells express antibodies reactive with antigenic epitopes expressed on the surface of common bacteria. Blood 2006 108 : 12a.
91. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003 21 : 841 94.
92. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005 352 : 804 15.
93. Petlickovski A, Laurenti L, Li X et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005 105 : 4820 7.
94. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004 103 : 4389 95.
95. Ochsenbein AF, Fehr T, Lutz C et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999 286 : 2156 9.
96. Seidl KJ, MacKenzie JD, Wang D et al. Frequent occurrence of identical heavy and light chain Ig rearrangements. Int Immunol 1997 9 : 689 702.
97. Tarlinton D, Stall AM, Herzenberg LA. Repetitive usage of immunoglobulin VH and D gene segments in CD5+ Ly-1 B clones of (NZB × NZW)F1 mice. EMBO J 1988 7 : 3705 10.